{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:54:41Z","timestamp":1792457681471,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05388-0","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T09:29:11Z","timestamp":1767432551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Retrospective analysis of the impact of antidepressants with anti-acid sphingomyelinase activity on survival of patients with glioblastoma"],"prefix":"10.1007","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3701-8274","authenticated-orcid":false,"given":"Cindy M.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Henrique","family":"Medeiros Geraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik P.","family":"Sulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"issue":"1","key":"5388_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s41984-024-00294-5","volume":"39","author":"M Sabouri","year":"2024","unstructured":"Sabouri M, Dogonchi AF, Shafiei M, Tehrani DS (2024 Jun) Survival rate of patient with glioblastoma: a population-based study. Egypt J Neurosurg 39(1):42. https:\/\/doi.org\/10.1186\/s41984-024-00294-5","journal-title":"Egypt J Neurosurg"},{"issue":"4","key":"5388_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/OP.22.00476","volume":"19","author":"R Kotecha","year":"2023","unstructured":"Kotecha R, Odia Y, Khosla AA, Ahluwalia MS (2023 Apr) Key clinical principles in the management of glioblastoma. JCO Oncol Pract 19(4):180\u2013189. https:\/\/doi.org\/10.1200\/OP.22.00476","journal-title":"JCO Oncol Pract"},{"key":"5388_CR3","doi-asserted-by":"publisher","unstructured":"Kazda T et al (2018 Jun) Radiotherapy of glioblastoma 15 years after the landmark stupp\u2019s trial: more controversies than standards? Radiol Oncol 52(2):121\u2013128. https:\/\/doi.org\/10.2478\/raon-2018-0023","DOI":"10.2478\/raon-2018-0023"},{"key":"5388_CR4","doi-asserted-by":"publisher","unstructured":"Stupp R et al (2009 May) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459\u2013466. https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7","DOI":"10.1016\/S1470-2045(09)70025-7"},{"key":"5388_CR5","doi-asserted-by":"publisher","unstructured":"Stupp R et al (2015 Dec) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. Jama 314(23):2535\u20132543. https:\/\/doi.org\/10.1001\/jama.2015.16669","DOI":"10.1001\/jama.2015.16669"},{"key":"5388_CR6","doi-asserted-by":"publisher","unstructured":"Bi J et al (2021 Nov) Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Rep 37(5):109957. https:\/\/doi.org\/10.1016\/j.celrep.2021.109957","DOI":"10.1016\/j.celrep.2021.109957"},{"key":"5388_CR7","doi-asserted-by":"publisher","unstructured":"Hegi ME et al (2005 Mar) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331","DOI":"10.1056\/NEJMoa043331"},{"issue":"1","key":"5388_CR8","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.1038\/s41467-023-41694-9","volume":"14","author":"I Noorani","year":"2023","unstructured":"Noorani I, de la Rosa J (2023 Sep) Breaking barriers for glioblastoma with a path to enhanced drug delivery. Nat Commun 14(1):5909. https:\/\/doi.org\/10.1038\/s41467-023-41694-9","journal-title":"Nat Commun"},{"key":"5388_CR9","doi-asserted-by":"publisher","unstructured":"Sun Y et al (2023 Apr) Drug permeability: from the blood-brain barrier to the peripheral nerve barriers. Adv Ther (Weinh) 6(4):2200150. https:\/\/doi.org\/10.1002\/adtp.202200150","DOI":"10.1002\/adtp.202200150"},{"key":"5388_CR10","doi-asserted-by":"publisher","unstructured":"Kornhuber J et al (2008 Jan) Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem 51(2):219\u2013237. https:\/\/doi.org\/10.1021\/jm070524a","DOI":"10.1021\/jm070524a"},{"key":"5388_CR11","doi-asserted-by":"publisher","unstructured":"Petersen NHT et al (2013 Sep) Transformation-associated changes in Sphingolipid metabolism sensitize cells to lysosomal Cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell 24(3):379\u2013393. https:\/\/doi.org\/10.1016\/j.ccr.2013.08.003","DOI":"10.1016\/j.ccr.2013.08.003"},{"key":"5388_CR12","doi-asserted-by":"publisher","unstructured":"Xiang H, Jin S, Tan F, Xu Y, Lu Y, Wu T (2021 Jul) Physiological functions and therapeutic applications of neutral sphingomyelinase and acid sphingomyelinase. Biomed Pharmacother 139:111610. https:\/\/doi.org\/10.1016\/j.biopha.2021.111610","DOI":"10.1016\/j.biopha.2021.111610"},{"key":"5388_CR13","doi-asserted-by":"publisher","unstructured":"Hoertel N et al (2022 Mar) Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study. Transl Psychiatry 12:90. https:\/\/doi.org\/10.1038\/s41398-022-01804-5","DOI":"10.1038\/s41398-022-01804-5"},{"key":"5388_CR14","doi-asserted-by":"publisher","unstructured":"Gulbins E et al (2013 Jul) Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nat Med 19(7):934\u2013938. https:\/\/doi.org\/10.1038\/nm.3214","DOI":"10.1038\/nm.3214"},{"key":"5388_CR15","doi-asserted-by":"publisher","unstructured":"Pinto C, Sousa D, Ghilas V, Dardis A, Scarpa M, Macedo MF (2021 Jan) Acid sphingomyelinase deficiency: a clinical and immunological perspective. Int J Mol Sci 22(23). https:\/\/doi.org\/10.3390\/ijms222312870","DOI":"10.3390\/ijms222312870"},{"key":"5388_CR16","doi-asserted-by":"publisher","unstructured":"Wang Q et al (2024) Interplay of Sphingolipid metabolism in predicting prognosis of GBM patients: towards precision immunotherapy. J Cancer 15(1):275\u2013292. https:\/\/doi.org\/10.7150\/jca.89338","DOI":"10.7150\/jca.89338"},{"key":"5388_CR17","doi-asserted-by":"publisher","unstructured":"Warda M, Tekin S, Gamal M, Khafaga N, \u00c7elebi F, Tarantino G (2025 Apr) Lipid rafts: novel therapeutic targets for metabolic, neurodegenerative, oncological, and cardiovascular diseases. Lipids Health Dis 24:147. https:\/\/doi.org\/10.1186\/s12944-025-02563-0","DOI":"10.1186\/s12944-025-02563-0"},{"issue":"8","key":"5388_CR18","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/npp.2011.57","volume":"36","author":"J Zschocke","year":"2011","unstructured":"Zschocke J, Zimmermann N, Berning B, Ganal V, Holsboer F, Rein T (2011 Jul) Antidepressant drugs diversely affect autophagy pathways in astrocytes and neurons-dissociation from cholesterol homeostasis. Neuropsychopharmacology 36(8):1754\u20131768. https:\/\/doi.org\/10.1038\/npp.2011.57","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"5388_CR19","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/s41380-018-0090-9","volume":"23","author":"A Gulbins","year":"2018","unstructured":"Gulbins A (2018 Dec) Antidepressants act by inducing autophagy controlled by sphingomyelin-ceramide. Mol Psychiatry 23(12):2324\u20132346. https:\/\/doi.org\/10.1038\/s41380-018-0090-9","journal-title":"Mol Psychiatry"},{"key":"5388_CR20","doi-asserted-by":"publisher","first-page":"1345190","DOI":"10.3389\/fonc.2024.1345190","volume":"14","author":"J Wang","year":"2024","unstructured":"Wang J et al (2024 Mar) Tumor treating fields in glioblastoma: long-term treatment and high compliance as favorable prognostic factors. Front Oncol 14:1345190. https:\/\/doi.org\/10.3389\/fonc.2024.1345190","journal-title":"Front Oncol"},{"issue":"33","key":"5388_CR21","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY et al (2023 Nov) RANO 2.0: update to the Response Assessment in Neuro-Oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol 41(33):5187\u20135199. https:\/\/doi.org\/10.1200\/JCO.23.01059","journal-title":"J Clin Oncol"},{"issue":"11","key":"5388_CR22","doi-asserted-by":"publisher","first-page":"5700","DOI":"10.3390\/ijms22115700","volume":"22","author":"C Rhein","year":"2021","unstructured":"Rhein C et al (2021 May) mRNA expression of SMPD1 encoding acid sphingomyelinase decreases upon antidepressant treatment. Int J Mol Sci 22(11):5700. https:\/\/doi.org\/10.3390\/ijms22115700","journal-title":"Int J Mol Sci"},{"issue":"2","key":"5388_CR23","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3892\/or.2016.4860","volume":"36","author":"J Ma","year":"2016","unstructured":"Ma J et al (2016 Aug) Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells. Oncol Rep 36(2):676\u2013684. https:\/\/doi.org\/10.3892\/or.2016.4860","journal-title":"Oncol Rep"},{"key":"5388_CR24","doi-asserted-by":"publisher","first-page":"904701","DOI":"10.3389\/fphar.2022.904701","volume":"13","author":"S Shao","year":"2022","unstructured":"Shao S, Zhuang X, Zhang L, Qiao T (2022 May) Antidepressants fluoxetine mediates endoplasmic reticulum stress and autophagy of non-small cell lung cancer cells through the ATF4-AKT-mTOR signaling pathway. Front Pharmacol 13:904701. https:\/\/doi.org\/10.3389\/fphar.2022.904701","journal-title":"Front Pharmacol"},{"issue":"6","key":"5388_CR25","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1074\/jbc.M112.432344","volume":"288","author":"MR Chikka","year":"2013","unstructured":"Chikka MR, McCabe DD, Tyra HM, Rutkowski DT (2013 Feb) C\/EBP homologous protein (chop) contributes to suppression of metabolic genes during endoplasmic reticulum stress in the liver. J Biol Chem 288(6):4405\u20134415. https:\/\/doi.org\/10.1074\/jbc.M112.432344","journal-title":"J Biol Chem"},{"key":"5388_CR26","doi-asserted-by":"publisher","first-page":"113609","DOI":"10.1016\/j.fct.2023.113609","volume":"173","author":"J Yang","year":"2023","unstructured":"Yang J et al (2023 Mar) Inhibition of ATF4-mediated elevation of both autophagy and AKT\/mTOR was involved in antitumorigenic activity of curcumin. Food Chem Toxicol 173:113609. https:\/\/doi.org\/10.1016\/j.fct.2023.113609","journal-title":"Food Chem Toxicol"},{"issue":"4","key":"5388_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jnci.2016.07.001","volume":"28","author":"S Mallick","year":"2016","unstructured":"Mallick S, Benson R, Hakim A, Rath GK (2016 Dec) Management of glioblastoma after recurrence: a changing paradigm. J Egypt Natl Cancer Inst 28(4):199\u2013210. https:\/\/doi.org\/10.1016\/j.jnci.2016.07.001","journal-title":"J Egypt Natl Cancer Inst"},{"key":"5388_CR28","unstructured":"\u201cOverall survival in patients with recurrent glioblastomas with combination chemotherapy and tumor treating fields (TTF)- ASCO. Accessed: Sep. 2, 2025. [Online Available]. https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT423900"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05388-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05388-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05388-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:47:05Z","timestamp":1769773625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05388-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5388"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05388-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8022772\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to the NYU Langone Health IRB policy and the U.S. Common Rule (45 CFR 46.104[d] [\n                      \n                      ]), this retrospective review of de-identified patient records was exempt from formal ethics approval and informed consent requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Non-financial interests"}},{"value":"Erik P. Sulman received institutional research funding from Novocure.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}